Hikma Pharmaceuticals PLC (HIK)

1,704.00 +27.50 (+1.64%)
Closed GBP Disclaimer

HIK Financial Summary

For the fiscal year ended 31 December 2021, Hikma Pharmaceuticals Plc revenues increased 9% to $2.55B. Net income decreased 2% to $421M. Revenues reflect Generic Pharmaceuticals segment increase of 10% to $820M, Injectable Pharmaceuticals segment increase of 8% to $1.05B, Branded Pharmaceuticals segment increase of 9% to $669M, United States segment increase of 7% to $1.51B, Middle East and North Africa segment increase of 10% to $847M.
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
HIK
Gross margin TTM 50.96%
Operating margin TTM 23.42%
Net Profit margin TTM 16.45%
Return on Investment TTM 13.05%
Total Revenue
Net Income
Title
Dec 31, 2021
Jun 30, 2021
Dec 31, 2020
Jun 30, 2020
Total Revenue 1,337 1,216 1,209 1,132
Gross Profit 685 616 611 602
Operating Income 255 343 309 293
Net Income 173 248 219 212
Clear All
0Selected
Please try another search
HIK
Quick Ratio MRQ 1.38
Current Ratio MRQ 2.06
LT Debt to Equity MRQ 29.56%
Total Debt to Equity MRQ 34.49%
Total Assets
Total Liabilities
Title
Dec 31, 2021
Jun 30, 2021
Dec 31, 2020
Jun 30, 2020
Total Assets 4,372 4,180 4,135 3,970
Total Liabilities 1,919 1,890 2,000 2,080
Total Equity 2,453 2,290 2,135 1,890
Clear All
0Selected
Please try another search
HIK
Cash Flow/Share TTM 2.01
Revenue/Share TTM 8.72
Operating Cash Flow 62.80%
Cash
Net Change in Cash
Title
Dec 31, 2021
Jun 30, 2021
Dec 31, 2020
Jun 30, 2020
Cash From Operating Activities 638 224 464 292
Cash From Investing Activities -238 -104 -283 -100
Cash From Financing Activities -287 -112 -298 -220
Net Change in Cash 103 -1 -119 -29
Clear All
0Selected
Please try another search

* In Millions of USD (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.